

Primary Cutaneous Gamma-Delta T-cell Lymphoma: Not an Aggressive Disease in All Cases

Mehdi KHALLAAYOUNE¹, Florent GRANGE², Morgane CONDAMINA², Vanessa SZABLEWSKI³, Bernard GUILLOT¹ and Olivier DEREURE^{1*}

¹Department of Dermatology, University of Montpellier and INSERM U1058, Hôpital Saint-Eloi, 80 avenue Augustin Fliche, FR-34295 Montpellier Cedex 5, ²Department of Dermatology, University of Reims, Reims, and ³Laboratory of Pathology, University of Montpellier, Montpellier, France. *E-mail: o-dereure@chu-montpellier.fr

Accepted Oct 14, 2019; Epub ahead of print Oct 14, 2019

Primary cutaneous gamma-delta T-cell lymphoma (PCGDTCL) is a rare form of primary cutaneous lymphoma characterized by a clonal proliferation of mature γ/δ T lymphocytes. PCGDTCL is usually considered an aggressive and rapidly evolving malignancy. Contrasting with this pattern, we hereby report 2 unusual cases with a protracted indolent evolution.

CASE REPORTS

Patient 1. A 68-year-old woman presented with relapsing ulcerated skin nodules, treated with several courses of antibiotics during the preceding 6 years, along with more recent fever and night sweating. Initial physical examination revealed multiple subcutaneous ulcerated nodules located on her limbs and trunk (**Fig. 1**) some of them evolving toward spontaneous regression according to the patient. A picture of an earlier lesion was obtained retrospectively, showing a thick ulcerated plaque clinically identical to later lesions thus confirming a long initial indolent course. No superficial lymphadenopathy was present and general status was conserved. Histopathological examination of a nodule revealed a dense dermal and subcutaneous infiltrate of medium-to-large lymphocytes displaying a CD3⁺ CD4⁺ CD8⁻ CD56⁺ EBER granzyme B⁺ TIA1⁺ TCR β phenotype. Staging with positron emission tomography (PET) showed no suspect hypermetabolism of internal organs and deep lymph nodes. Based on these data, a diagnosis of PCGDTCL was established and a first-line treatment with methotrexate 20 mg/week was introduced owing to the protracted indolent evolution, initially associated with prednisone on account of biological elements of macrophage activation syndrome (MAS) with no related clinical symptoms. However, systemic chemotherapy with cyclophosphamide, adriamycin, vincristin and prednisone (CHOP) was rapidly implemented due to the uncontrolled progression of skin lesions but had to be interrupted after 4 courses owing to infectious complications. The patient finally presented with a deteriorated general condition, dyspnea and relapse of MAS and died one month after the last cycle of chemotherapy.

Patient 2. A 69-year-old man was referred for evaluation of recurrent, self-regressive cutaneous nodules of a 2-year duration, with no significant extracutaneous manifestations. Initial biopsies were consistent with primary cutaneous CD30⁺ lymphoproliferation, and cutaneous lesions were treated with topical steroids. After 2 years of relapsing and remitting lesions, he finally presented with non-regressive subcutaneous nodules on the legs and trunk. Histopathological examination then revealed a dense predominant dermal and subcutaneous infiltrate of small to medium-size lymphocytes (**Fig. S1**¹) expressing a CD3⁺ CD4⁻ CD8⁻ CD56⁻ granzyme B⁺ TIA-1⁺ TCR β ⁻ TCR γ ⁺ phenotype (**Fig. S2**¹), whereas GeneScan analysis identified a dominant T-cell population in skin lesions. PET did not display any hypermetabolism suspect of extracutaneous involvement. A diagnosis of PCGDTCL was retained and a treatment with methotrexate 15 mg/week was started. Since no improvement was obtained after 5 months, pegylated liposomal doxorubicin was subsequently introduced replaced after 7 cycles



Fig. 1. Patient 1: multiple ulcerated nodules on the abdomen.

by polychemotherapy with CHOP owing to iatrogenic peripheral neuropathy. This latter therapy was efficient and remained well tolerated after 9 cycles (7 CHOP and 2 COP) with no worsening of peripheral neurotoxicity. No skin progression nor extracutaneous involvement was observed 24 months after the last course of chemotherapy and more than 5 years after the first occurrence of cutaneous nodules.

DISCUSSION

PCGDTCL is a rare and usually aggressive malignancy, accounting for less than 1% of primary cutaneous lymphomas overall. Patients usually present with sometimes ulcerated or necrotic panniculitis-like plaques, nodules and tumours, mainly located on the limbs and the trunk (1). Histopathological and immunohistochemical analysis typically display an atypical lymphoid infiltrate, involving the epidermis, dermis, and/or subcutis, consisting of CD3⁺ CD4⁻ CD5⁻ TCR β ⁻ TCR γ ⁺ CD8⁻ medium to large-size cells with variable expression of CD7 and CD56 and a strong expression of the cytotoxic markers granzyme B and TIA-1 (2). This entity usually displays an aggressive clinical course with a median overall survival of 15 months (2), the frequent occurrence of MAS and a poor response to treatment including systemic polychemotherapy (3).

However, an increasing corpus of reports suggests the existence of a less frequently encountered subset with an allegedly more “indolent” or “smouldering” clinical course, variable clinical and histological presentations (4–12) and an overall survival that may range from 2 (4) to more than 15 years (10). Of note, the accurate nature of this “indolent”

¹<https://doi.org/10.2340/00015555-3340>

behaviour appears relatively ambiguous in earlier reports, since it may reflect variable underlying considerations including a less-than-expected clinical aggressiveness, a protracted overall survival (usually estimated since first occurrence of skin lesions) and/or a more favourable response to treatment. More specifically, 18 of such reported cases showed an overall survival exceeding twice the general median figure of 15 months and our 2 cases are consistent with these data (survival of more than 6 and 5 years, respectively, after first occurrence of skin lesions).

In this particular subset, regardless of its likely heterogeneity, clinical presentation appears to be similar to the main, aggressive subset with nodules, indurated plaques, ulcers or blistering lesions (11) located mainly on the limbs and trunk but which may also affect the face (5, 11) or display a widespread distribution. Interestingly Merrill et al. (13) suggested that a predominantly epidermotropic pattern might be associated with a more favourable outcome, although most other reported cases of “indolent” PCGDTCL displayed a more usual predominant dermal and/or subcutaneous involvement as in our 2 patients, even though a sparse epidermotropism was occasionally observed in patient 2. Atypical expression of CD30, CD4 or TCR β F1 might also be associated with a more indolent course (7), a data consistent with CD30 expression and an initial misdiagnosis of primary cutaneous CD30⁺ lymphoproliferation in our second patient.

This “smouldering” subset PCGDTCL must be separated from lupus erythematosus panniculitis and panniculitis-like subcutaneous T-cell lymphomas, although they may share some clinical and pathological features, including an initially indolent outcome. Additional differential diagnoses include other primary cutaneous T-cell lymphomas and a number of reactive conditions with unusual expression of TCR γ , such as mycosis fungoides (14), primary cutaneous CD30⁺ lymphoproliferations (15) and pityriasis lichenoides et varioliformis acuta (16).

Long-term outcome in this particular subset is still uncertain, as the overall survival may widely vary across reported cases. Despite the report of protracted complete remissions in several cases (5–7), most authors emphasize that the large majority of patients with so-called smouldering PCGDTCL eventually evolve toward a more usual aggressive form after an initial indolent course with fatal evolution occurring up to 15 years after initial diagnosis (10). These findings are consistent with our first patient’s outcome and clearly raise the issue of considering an (relatively) early, aggressive treatment in some patients during the initial, indolent phase of the disease as in our second case, taking into account age, comorbidities and general status even though there is currently no efficient way to anticipate final outcome on an individual basis. However, such a strategy must be discussed on a case-by-case basis since it is questionable in the most fragile patients owing to possible unnecessary morbidity and mortality induced

by toxic treatments that may include hematopoietic stem cell transplantation (17). In all cases, close clinical and morphological monitoring remains mandatory to quickly identify a shift to a more “classical”, aggressive form.

REFERENCES

1. Junkins-Hopkins JM. Aggressive cutaneous T-cell lymphomas. *Sem Diag Pathol* 2017; 34: 44–59.
2. Guitart J, Weisenburger DD, Subtil A, Kim E, Wood G, Duvic M, et al. Cutaneous $\gamma\delta$ T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. *Am J Surg Pathol* 2012; 36: 1656–1665.
3. Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. *Blood* 2019; 133: 1703–1714.
4. Benecke J, Géraud C, Nicolay JP. Cutaneous gamma-delta T-cell lymphoma with an initially indolent course mimicking lupus panniculitis. *Acta Derm Venereol* 2017; 97: 665–666.
5. Ali L, Young MR, Bayerl MG, Helm KF, Clarke LE. Gamma-delta T-cell lymphoma arising in a long-standing cutaneous plaque. *J Cutan Pathol* 2015; 42: 987–991.
6. Alexander RE, Webb AR, Abuel-Hajja M, Czader M. Rapid progression of primary cutaneous gamma-delta T-cell lymphoma with an initial indolent clinical presentation. *Am J Dermatopathol* 2014; 36: 839–842.
7. Vin H, Talpur R, Tetzlaff MT, Duvic M. T-cell receptor- γ in gamma-delta phenotype cutaneous T-cell lymphoma can be accompanied by atypical expression of CD30, CD4, or TCR β F1 and an indolent clinical course. *Clin Lymphoma Myeloma Leuk* 2014; 14: 195–200.
8. Endly DC, Weenig RH, Peters MS, Viswanatha DS, Comfere NI. Indolent course of cutaneous gamma-delta T-cell lymphoma. *J Cutan Pathol* 2013; 40: 896–902.
9. Magro CM, Wang X. Indolent primary cutaneous gamma/delta T-cell lymphoma localized to the subcutaneous panniculus and its association with atypical lymphocytic lobular panniculitis. *Am J Clin Pathol* 2012; 138: 50–56.
10. Hosler GA, Liégeois N, Anhalt GJ, Moresi JM. Transformation of cutaneous gamma/delta T-cell lymphoma following 15 years of indolent behavior. *J Cutan Pathol* 2008; 35: 1063–1067.
11. Kempf W, Kazakov DV, Scheidegger PE, Schlaak M, Tantcheva-Poor I. Two cases of primary cutaneous lymphoma with a $\gamma\delta$ + phenotype and an indolent course: further evidence of heterogeneity of cutaneous $\gamma\delta$ + T-cell lymphomas. *Am J Dermatopathol* 2014; 36: 570–577.
12. Hosler GA, Liégeois N, Anhalt GJ, Moresi JM. Transformation of cutaneous gamma/delta T-cell lymphoma following 15 years of indolent behavior. *J Cutan Pathol* 2008; 35: 1063–1067.
13. Merrill ED, Agbay R, Miranda RN, Aung PP, Tetzlaff MT, Young KH et al. Primary cutaneous T-cell lymphomas showing gamma-delta ($\gamma\delta$) phenotype and predominantly epidermotropic pattern are clinicopathologically distinct from classic primary cutaneous $\gamma\delta$ T-cell lymphomas. *Am J Surg Pathol* 2017; 41: 204–215.
14. Caballero A, Novelli S, Mozos A, Muret PG, Sierra J, Briones J. TCR-gamma expression in primary cutaneous T-cell lymphomas. *Am J Surg Pathol* 2013; 37: 375–384.
15. Badje ED, Tejasvi T, Hristov A. $\gamma\delta$ lymphomatoid papulosis type D: a histologic mimic of primary cutaneous $\gamma\delta$ T-cell lymphoma. *J Am Acad Dermatol Case Rep* 2019; 5: 264–266.
16. King RL, Yan AC, Sekiguchi DR, Choi JK. Atypical cutaneous $\gamma\delta$ T cell proliferation with morphologic features of lymphoma but with clinical features and course of PLEVA or lymphomatoid papulosis. *J Cutan Pathol* 2015; 42: 1012–1017.
17. Duarte RF, Schmitz N, Servitje O, Sureda A. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. *Bone Marrow Transplant* 2008; 41: 597–604.